EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer

Oncotarget

Volumn 5, Issue 17, 2014, Pages 7486-7497

  Serrano, Maria J ^a   Ortega, Francisco G ^a   Alvarez Cubero, Maria J ^a   Nadal, Rosa ^b   Sanchez Rovira, Pedro ^c   Salido, Marta ^d   Rodríguez, María ^d   García Puche, Jose L ^a   Delgado Rodriguez, Miguel ^c   Solé, Francisco ^e,f   García, Maria A ^g   Perán, Macarena ^a,c   Rosell, Rafael ^h,i   Marchal, Juan A ^a   Lorente, Jose A ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b Hospital de Niños de Barcelona   (Spain)

^c UNIVERSITY OF JAÉN   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE IJC   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

Apoptosis; Bcl 2; Breast cancer; Circulating tumor cells; EGFR; Epithelial mesenchymal transition; Slug; Vimentin

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; CD133 ANTIGEN; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MEMBRANE PROTEIN; TOPO2 PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VIMENTIN; EGFR PROTEIN, HUMAN; KERATIN; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CELL MIGRATION; CELL MOTILITY; CIRCULATING TUMOR CELL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; AGED; BIOSYNTHESIS; BREAST TUMOR; CONFOCAL MICROSCOPY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; MCF 7 CELL LINE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR EMBOLISM; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; BREAST NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KERATINS; MCF-7 CELLS; MICROSCOPY, CONFOCAL; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 84907484036     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2217     Document Type: Article

References (32)

1. Franken B, Degroot M, Mastboom W, Vermes I, Vanderpalen J, Tibbe A, Terstappen L. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 2012;14:133.
2. Stoletov K, Kato H, Zardouzian E, Kelber J, Yang J, Shattil S, Klemke. Visualizing extravasation dynamics of metastatic tumor cells. J. Cell. Sci. 2010; 123: 2332-2341.
3. Joosse SA, Hannemann J, Spötter J, Bauche A, Andreas A, Müller V, Pantel K. Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clinical Cancer Research. 2012; 18: 993-1003.
4. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nature Reviews Cancer. 2002; 2: 442-454.
5. Walia V, Yu Y, Cao D, Sun M, McLean J, Hollier B, Cheng J, Mani S, Premkumar L, Elble R. Loss of breast epithelial marker hCLCA2 promotes epithelial-to-mesenchymal transition and indicates higher risk of metastasis. Oncogene. 2012; 31: 2237-2246.
6. Bonnomet A, Brysse A, Tachsidis A, Waltham M, W. Thompson EW, Polette M, Gilles C. Epithelial-to-mesenchymal transitions and circulating tumor cells. J. Mammary Gland Biol. Neoplasia. 2010; 15: 261-273.
7. Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer. 2012; 12:91.
8. Jeong H, Ryu Y, An J, Lee Y, Kim A. Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathology. 2012; 60: E87-E95.
9. Shioiri M, Shida T, Koda K, Oda K, Seike K, Nishimura M, Takano S, Miyazaki M. Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br. J. Cancer. 2006; 94: 1816-1822.
10. Ueno NT, Zhang D. Targeting EGFR in triple negative breast cancer. Journal of Cancer. 2011; 2: 324.
11. Chang Z, Wei J, Qin C, Hao K, Tian X, Xie K, Xie X, Yang Y. Suppression of the epidermal growth factor receptor inhibits epithelial-mesenchymal transition in human pancreatic cancer PANC-1 cells. Dig. Dis. Sci. 2012; 57: 1181-1189.
12. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. 2004; 4: 448-456.
13. Kim Y, Koo KH, Sung JY, Yun U, Kim H. Anoikis resistance: an essential prerequisite for tumor metastasis. International journal of cell biology. 2012; 2012: 306879. doi: 10.1155/2012/306879.
14. Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 2011; 13:R59.
15. Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, Palazzo A, Saltarelli R, Spremberg F, Cortesi E. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res. Treat. 2011; 130: 449-455.
16. Bonnomet A, Syne L, Brysse A, Feyereisen E, Thompson E, Noël A, Foidart J, Birembaut P, Polette M, Gilles C. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene. 2011; 31: 3741-3753.
17. I. Desitter I, B. S. Guerrouahen BS, N. Benali-Furet N, J. Wechsler J, P. A. Jaenne PZ, Y. Kuang Y, M. Yanagita M, L. Wang L, J. A. Berkowitz JA, R. J. Distel RJ. A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res. 2011; 31: 427-441.
18. X. Fang X, Y. Cai Y, J. Liu J, Z. Wang Z, Q. Wu Q, Z. Zhang Z, C. Yang C, L. Yuan L, G. Ouyang G. Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. Oncogene. 2011; 30: 4707-4720.
19. Chao Y, Wu Q, Acquafondata M, Dhir R, Wells A. Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenvironment. 2012; 5: 19-28.
20. Zhang K, Chen D, Jiao X, Zhang S, Liu X, Cao J, Wu L, Wang D. Slug enhances invasion ability of pancreatic cancer cells through upregulation of matrix metalloproteinase-9 and actin cytoskeleton remodeling. Laboratory Investigation.2011; 91: 426-438.
21. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS Journal. 2010; 277: 301-308.
22. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009; 119: 1420.
23. Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D, Vadgama JV. Expression of Wnt3 Activates Wnt/β-Catenin Pathway and Promotes EMT-like Phenotype in Trastuzumab-Resistant HER2-Overexpressing Breast Cancer Cells. Molecular Cancer Research. 2012; 10: 1597-1606.
24. Lo H, Hsu S, Xia W, Cao X, Shih J, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung M. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res. 2007; 67: 9066-9076.
25. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ. Ciciliano JC, M. N. Wells MN, A. M. Shah AM. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013; 339: 580-584.
26. Schuster N, Krieglstein K. Mechanisms of TGF-β-mediated apoptosis. Cell Tissue Res. 2002; 307: 1-14.
27. Docherty NG, O'Sullivan OE, Healy A, M. Murphy M, O'Neill AJ, Fitzpatrick JM, Watson RW. TGF-beta1-induced EMT can occur independently of its proapoptotic effects and is aided by EGF receptor activation. Am J Physiol Renal Physiol.2006;290:1202-1212.
28. Zuo J, Ishikawa T, Boutros S, Xiao Z, Humtsoe JO, Kramer RH. Bcl-2 overexpression induces a partial epithelial to mesenchymal transition and promotes squamous carcinoma cell invasion and metastasis. Molecular Cancer Research.2010; 8: 170-182.
29. Chang T, Tsai M, Su K, Wu S, Huang C, Yu S, Yu Y, Lan C, Yang C, Lin S. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. American journal of respiratory and critical care medicine. 2011; 183: 1071-1079.
30. The Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61-70.
31. Prat A, M. Perou CM. Deconstructing the molecular portraits of breast cancer. Molecular oncology. 2011; 5: 5-23.
32. Nadal R, A. Fernandez A, Sanchez-Rovira P, Salido M, Rodríguez M, García-Puche JL, Macià M, Corominas JM, Delgado-Rodriguez M, Gonzalez L. Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res. 2012; 14: R71.